keyword
MENU ▼
Read by QxMD icon Read
search

LDV

keyword
https://www.readbyqxmd.com/read/29771105/direct-acting-antiviral-agents-in-patients-with-hepatitis-c-genotype-1-4-infections-in-a-tertiary-hospital
#1
J C Del Rio-Valencia, R Asensi-Diez, L Villalobos-Torres, I Muñoz Castillo
OBJECTIVE: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Six different genotypes (GT) of HCV (genotypes 1-6) have been identified. The genotype is clinically relevant since the majority of current direct antiviral agents (DAA´s) do not have pangenotypic efficacy. The purpose of this study was to describe the clinical characteristics of real world patients and evaluate the effectiveness of different treatment regimens. METHODS: Retrospective and observational study carried out in a third level hospital...
May 16, 2018: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/29766745/incidence-of-acute-kidney-injury-in-patients-co-infected-with-hiv-and-hepatitis-c-virus-receiving-tenofovir-disoproxil-fumarate-and-ledipasvir-sofosbuvir-in-a-real-world-urban-ryan-white-clinic
#2
Jessica L Michal, Saira Rab, Manish Patel, Alison Kyle, Lesley Miller, Kirk A Easley, Aley Kalapila
Background Ledipasvir/sofosbuvir (LDV/SOF), an antiviral treatment for hepatitis C virus (HCV), and tenofovir disoproxil fumarate (TDF), an antiretroviral for treating human immunodeficiency virus (HIV), may be co-administered in patients co-infected with these viruses. A drug interaction between LDV and TDF could increase TDF-associated nephrotoxicity rates; however, there is minimal clinical evidence describing acute kidney injury (AKI) rates in this population. Setting This study was conducted at a Ryan White-funded facility in Atlanta, Georgia, that cares for over 5,000 patients with AIDS...
May 16, 2018: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/29743791/impact-of-direct-acting-antiviral-therapy-for-treatment-of-hepatitis-c-genotypes-1-3-and-4-a-real-life-experience-from-india
#3
Varun Mehta, Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez, Ajit Sood
Objective: To assess impact of Direct Acting Antiviral (DAA) therapies for treatment of Hepatitis C Virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India. Methods: Adults with chronic HCV infection treated with Sofosbuvir (SOF) and Ledipasvir (LDV) (genotypes 1 and 4) or SOF and Daclatasvir (DCV) (genotype 3), with or without Ribavirin (RBV) between December 2015 and December 2016 were included. The primary endpoint was Sustained Virological Response at Post-treatment Week 12 (SVR12)...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29742470/real-life-efficacy-of-ledipasvir-sofosbuvir-in-hepatitis-c-genotype-4-infected-patients-with-advanced-liver-fibrosis-and-decompensated-cirrhosis-%C3%A2-%C3%A2-%C3%A2
#4
Faisal M Sanai, Ibrahim H Altraif, Khalid Alswat, Adnan AlZanbagi, Mohamed A Babatin, Abdallah AlMousa, Nawaf H Almutairi, Mohammed S Aljawad, Abdullah S Alghamdi, Abdulrahman A Aljumah, Abduljaleel M Alalwan, Waleed K Al-Hamoudi, Abdullah M Assiri, Yaser Dahlan, Ashwaq Alsahafi, Hammad S Alothmani, Mohammed S AlSaleemi, Waleed A Mousa, Ali Albenmousa, Abdelrahman Awny, Haziz Albiladi, Ayman A Abdo, Hamdan AlGhamdi
Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SOF with or without ribavirin (RBV) in GT4-infected patients with compensated and decompensated cirrhosis. PATIENTS & METHODS: This observational cohort (n=213) included GT4 treatment-naïve (59.6%) and -experienced (40.4%) patients with advanced fibrosis (F3, Metavir; n=30), compensated (F4, n=135) and decompensated cirrhosis (n=48) treated for 12 (n=202) or 24 weeks (n=11) with LDV/SOF...
May 6, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29726498/two-dimensional-laser-doppler-velocimeter-and-its-integrated-navigation-with-a-strapdown-inertial-navigation-system
#5
Qi Wang, Chunfeng Gao, Jian Zhou, Guo Wei, Xiaoming Nie, Xingwu Long
In the field of land navigation, a laser Doppler velocimeter (LDV) can be used to provide the velocity of a vehicle for an integrated navigation system with a strapdown inertial navigation system. In order to suppress the influence of vehicle jolts on a one-dimensional (1D) LDV, this paper designs a split-reuse two-dimensional (2D) LDV. The velocimeter is made up of two 1D velocimeter probes that are mirror-mounted. By the different effects of the vertical vibration on the two probes, the velocimeter can calculate the forward velocity and the vertical velocity of a vehicle...
May 1, 2018: Applied Optics
https://www.readbyqxmd.com/read/29626296/real-world-efficacy-and-safety-of-ledipasvir-and-sofosbuvir-in-patients-with-hepatitis-c-virus-genotype-1-infection-a-nationwide-multicenter-study-by-the-japanese-red-cross-liver-study-group
#6
Keiji Tsuji, Masayuki Kurosaki, Jun Itakura, Nami Mori, Shintaro Takaki, Chitomi Hasebe, Takehiro Akahane, Kouji Joko, Hitoshi Yagisawa, Jirou Takezawa, Ryou Nakata, Atsunori Kusakabe, Yuji Kojima, Hiroyuki Kimura, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Masahiko Kondou, Chikara Ogawa, Yasushi Uchida, Tetsuro Sohda, Ryouichi Narita, Namiki Izumi
BACKGROUND: We aimed to describe the real-world efficacy and safety of combination therapy with ledipasvir and sofosbuvir (LDV/SOF) for chronic hepatitis C virus (HCV) genotype 1 (GT1) infection. METHODS: This retrospective analysis of a prospective, nationwide, multicenter registry included GT1-infected patients treated with LDV/SOF for 12 weeks. We assessed the rate of sustained virological response at 12 weeks post-treatment (SVR12), incidence of adverse events, and serum markers of hepatocellular carcinoma (HCC)...
April 6, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29618647/identification-of-the-rna-pseudoknot-within-the-3-end-of-prrsv-genome-as-pathogen-associated-molecular-pattern-to-activate-antiviral-signaling-via-rig-i-and-tlr3
#7
Sha Xie, Xin-Xin Chen, Songlin Qiao, Rui Li, Yangang Sun, Shuangfei Xia, Lin-Jian Wang, Xuegang Luo, Ruiguang Deng, En-Min Zhou, Gai-Ping Zhang
Once infected by viruses, cells can detect pathogen associated molecular patterns (PAMPs) on viral nucleic acid by host pattern recognition receptors (PRRs) to initiate the antiviral response. Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of porcine reproductive and respiratory syndrome (PRRS), characterized by reproductive failure in sows and respiratory diseases in pigs of different ages. To date, the sensing mechanism of PRRSV has not been elucidated. Here, we reported that the pseudoknot region residing in the 3' untranslated regions (UTR) of PRRSV genome, which has been proposed to regulate RNA synthesis and virus replication, was sensed as non-self by retinoic acid-inducible gene I (RIG-I) and Toll like receptor (TLR3) and strongly induced type I IFNs and interferon-stimulated genes (ISGs) in porcine alveolar macrophages (PAMs)...
April 4, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29601403/differential-timing-of-cholesterol-increase-during-successful-hcv-therapy-impact-of-type-of-drug-combination
#8
Antonio Rivero-Juarez, Angela Camacho, Teresa Brieva, Mario Frias, Pedro Lopez-Lopez, María A Risalde, Isabel Machuca, Juan J Caston, Antonio Martínez Peinado, Antonio Rivero
OBJECTIVE: to evaluate factors associated with increased serum cholesterol levels during Interferon-free (IFN-free) Hepatitis C virus (HCV) therapy. DESIGN: Prospective longitudinal study METHODS:: HIV-infected patients who started and successfully completed IFN-free therapy for chronic HCV infection were included. Patients were treated using two different regimens, based on the clinician's opinion: sofosbuvir and ledipasvir (SOF/LDV), or paritaprevir co-administered with ombitasvir and Dasabuvir (PrOD)...
March 27, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29599610/successful-combination-of-direct-antiviral-agents-in-liver-transplanted-patients-with-recurrent-hepatitis-c-virus
#9
Christian Rupp, Theresa Hippchen, Manuel Neuberger, Peter Sauer, Jan Pfeiffenberger, Wolfgang Stremmel, Daniel Nils Gotthardt, Arianeb Mehrabi, Karl-Heinz Weiss
AIM: To analyze the safety and efficiency of direct-acting antiviral (DAA) regimens in liver-transplanted patients with hepatitis C virus (HCV) reinfection. METHODS: Between January 2014 and December 2016, 39 patients with HCV reinfection after liver transplantation were treated at our tertiary referral center with sofosbuvir (SOF)-based regimens, including various combinations with interferon (IFN), daclatasvir (DAC), simeprivir (SIM) and/or ledipasvir (LDV). Thirteen patients were treated with SOF + IFN ± RBV...
March 28, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29573638/n-linoleoylamino-acids-as-chiral-probes-of-substrate-binding-by-soybean-lipoxygenase-1
#10
Charles H Clapp, Justin Pachuski, Natasha F Bassett, Kathleen A Bishop, Gillian Carter, Megan Young, Thomas Young, Yuhan Fu
Lipoxygenases catalyze the oxygenation of polyunsaturated fatty acids and their derivatives to produce conjugated diene hydroperoxides. Soybean lipoxygenase-1 (SBLO-1) has been the subject of intensive structural and mechanistic study, but the manner in which this enzyme binds substrates is uncertain. Previous studies suggest that the fatty acyl group of the substrate binds in an internal cavity near the catalytic iron with the polar end at the surface of the protein or perhaps external to the protein. To test this model, we have investigated two pairs of enantiomeric N-linoleoylamino acids as substrates for SBLO-1...
March 8, 2018: Bioorganic Chemistry
https://www.readbyqxmd.com/read/29569736/safety-and-efficacy-of-ledipasvir-sofosbuvir-with-or-without-ribavirin-in-hepatitis-c-genotype-1-patients-including-those-with-decompensated-cirrhosis-who-failed-prior-treatment-with-simeprevir-sofosbuvir
#11
A A Modi, H E Nazario, G R Gonzales, S A Gonzalez
BACKGROUND: Combination therapy of simeprevir (SIM)/sofosbuvir (SOF) is an approved treatment for hepatitis C genotype (gen) 1 with overall SVR12 rate of 85%-95%. The single tablet fixed-dose combination of ledipasvir (LDV)/SOF is also approved for gen 1 with sustained virologic response at 12 weeks (SVR12) rates ≥95%. No data are available on the efficacy of retreatment with LDV/SOF in patients who failed initial treatment with SIM/SOF. AIM: Our aim was to evaluate the efficacy of retreatment with LDV/SOF ± ribavirin (RBV) in gen 1 patients who had previously failed treatment with SIM/SOF...
March 23, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29536030/eight-weeks-of-ledipasvir-sofosbuvir-in-kidney-transplant-recipients-with-hepatitis-c-genotype-1-infection
#12
Jennifer S Husson, Bharath Ravichandran, Srijana Jonchhe, Shyamasundaran Kottilil, Eleanor Wilson
Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant recipients (RTRs), a patient population on lifelong immunosuppression. Here, we describe 3 RTRs who received 8 weeks of LDV/SOF, meeting the standard criteria for shortened treatment duration. All 3 patients tolerated treatment well and achieved sustained virologic response at 12 weeks (SVR 12)...
December 2017: Transplantation Direct
https://www.readbyqxmd.com/read/29522928/impact-damage-visualization-in-a-honeycomb-composite-panel-through-laser-inspection-using-zero-lag-cross-correlation-imaging-condition
#13
Donato Girolamo, Huan-Yu Chang, Fuh-Gwo Yuan
A fully non-contact laser-based nondestructive inspection (NDI) system is developed to detect and visualize damage in structures. The study focuses on the size quantification and characterization of a barely visible impact damage (BVID) in a honeycomb composite panel. The hardware consists of a Q-switched Nd:YAG pulse laser that probes the panel by generating broadband guided waves via thermo-elastic expansion. The laser, in combination with a set of galvano-mirrors is used to raster scan over a two-dimensional surface covering the damaged region of an impacted quasi-isotropic [60/0/-60]s honeycomb composite panel...
July 2018: Ultrasonics
https://www.readbyqxmd.com/read/29504692/efficacy-of-ledipasvir-sofosbuvir-with-or-without-ribavirin-for-12-weeks-in-genotype-1b-hcv-patients-previously-treated-with-a-nonstructural-protein-5a-inhibitor-containing-regimen
#14
Hiroki Ikeda, Tsunamasa Watanabe, Hirohito Shimizu, Tetsuya Hiraishi, Rena Kaneko, Toshiyuki Baba, Hideaki Takahashi, Kotaro Matsunaga, Nobuyuki Matsumoto, Hiroshi Yasuda, Chiaki Okuse, Shogo Iwabuchi, Michihiro Suzuki, Fumio Itoh
AIM: The therapeutic benefit of adding ribavirin (RBV) to 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) for patients who experienced failure of a previous nonstructural protein (NS) 5A inhibitor-containing regimen is unclear. METHODS: A total of 29 genotype 1b HCV patients who had failed prior daclatasvir (DCV) plus asunaprevir (ASV) treatment were retreated for 12 weeks of LDV/SOF, with or without RBV. Antiviral efficacy and predictive factors associating with a sustained virological response at 24 weeks (SVR24) were evaluated retrospectively...
March 5, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29466415/revisiting-policy-on-chronic-hcv-treatment-under-the-thai-universal-health-coverage-an-economic-evaluation-and-budget-impact-analysis
#15
Waranya Rattanavipapong, Thunyarat Anothaisintawee, Yot Teerawattananon
Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care's benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impact of introducing sofosbuvir-based regimens in the tax-based health insurance scheme. The Markov model was constructed to assess costs and benefits of the four treatment options that include: (i) current practice-peginterferon alfa (PEG) and ribavirin (RBV) for 24 weeks in genotype 3 and 48 weeks for other genotypes; (ii) Sofosbuvir plus peginterferon alfa and ribavirin (SOF+PEG-RBV) for 12 weeks; (iii) Sofosbuvir and daclatasvir (SOF+DCV) for 12 weeks; (iv) Sofosbuvir and ledipasvir (SOF+LDV) for 12 weeks for non-3 genotypes and SOF+PEG-RBV for 12 weeks for genotype 3 infection...
2018: PloS One
https://www.readbyqxmd.com/read/29454370/isolation-of-a-novel-rhabdovirus-from-an-insectivorous-bat-pipistrellus-kuhlii-in-italy
#16
Davide Lelli, Alice Prosperi, Ana Moreno, Chiara Chiapponi, Anna Maria Gibellini, Paola De Benedictis, Stefania Leopardi, Enrica Sozzi, Antonio Lavazza
BACKGROUND: Rhabdoviridae is one of the most ecologically diverse families of RNA viruses which can infect a wide range of vertebrates and invertebrates. Bats, among mammals, are pointed to harbor a significantly higher proportion of unknown or emerging viruses with zoonotic potential. Herein, we report the isolation of a novel rhabdovirus, detected in the framework of a virological survey on bats implemented in North Italy. METHODS: Virus isolation and identification were performed on samples of 635 bats by using cell cultures, negative staining electron microscopy and PCRs for different viruses...
February 17, 2018: Virology Journal
https://www.readbyqxmd.com/read/29453451/prevalence-and-impact-of-baseline-resistance-associated-substitutions-on-the-efficacy-of-ledipasvir-sofosbuvir-or-simeprevir-sofosbuvir-against-gt1-hcv-infection
#17
Gary P Wang, Norah Terrault, Jacqueline D Reeves, Lin Liu, Eric Li, Lisa Zhao, Joseph K Lim, Giuseppe Morelli, Alexander Kuo, Josh Levitsky, Kenneth E Sherman, Lynn M Frazier, Ananthakrishnan Ramani, Joy Peter, Lucy Akuskevich, Michael W Fried, David R Nelson
Baseline resistance-associated substitutions (RASs) have variable impacts in clinical trials but their prevalence and impact in real-world patients remains unclear. We performed baseline resistance testing using a commercial assay (10% cutoff) for 486 patients treated with LDV/SOF or SMV/SOF, with or without ribavirin, in the multi-center, observational HCV-TARGET cohort. Linkage of RASs was evaluated in selected samples using a novel quantitative single variant sequencing assay. Our results showed that the prevalence of NS3, NS5A, NS5B RASs was 45%, 13%, and 8%, respectively, and 10% of patients harbored RASs in 2 or more drug classes...
February 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29443068/design-and-characterization-methodology-for-efficient-wide-range-tunable-mems-filters
#18
Hasan Goktas
Here, we demonstrate the advantages of the laser Doppler vibrometer (LDV) over conventional techniques (the network analyzer), as well as the techniques to create an application-based microelectromechanical systems (MEMS) filter and how to use it efficiently (i.e., tuning the tuning-capability and avoiding both failure and stiction). LDV enables crucial measurements that are impossible with the network analyzer, such as higher mode detection (highly sensitive biosensor application) and resonance measurement for very small devices (fast prototyping)...
February 4, 2018: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/29430221/successful-treatment-of-oral-lichen-planus-with-direct-acting-antiviral-agents-after-liver-transplantation-for-hepatitis-c-virus-associated-hepatocellular-carcinoma
#19
Yumiko Nagao, Kazunori Nakasone, Tatsuji Maeshiro, Nao Nishida, Kanae Kimura, Yuji Kawahigashi, Yasuhito Tanaka, Michio Sata
Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF)...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29417191/-new-clinical-applications-for-laser-doppler-vibrometry-in-otology
#20
REVIEW
T Strenger, M Brandstetter, T Stark, F Böhnke
BACKGROUND: An instrument to measure vibration in the middle ear needs to be sensitive enough to detect displacement on a nanometer scale, yet not affect the vibration itself. Numerous techniques have been described in the literature, but laser Doppler vibrometry (LDV) has nowadays become established as the standard method in hearing research. OBJECTIVE: This article aims to present possible clinical applications of an LDV system in otology. MATERIALS AND METHODS: A commercially available single-point vibrometer was used...
April 2018: HNO
keyword
keyword
95665
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"